Netazepide is a highly selective CCK2R antagonist under development for the treatment of patients with gastric neuroendocrine tumors caused by hypergastrinemia secondary to chronic autoimmune atrophic gastritis. This evidence concerns the gene CCKBR and gastric neuroendocrine tumor, well differentiated, low or intermediate grade.